+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07143448

Phase 1b2 Randomized Study Evaluating Safety and Effects of HS235 Added to Background Treatment in Adults With Pulmonary Arterial Hypertension

Led by 35Pharma Inc., a GSK company · Updated on 2026-10-30

90

Participants Needed

7

Research Sites

35 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety, pharmacokinetics, pharmacodynamics, and effectiveness of HS235, an Activin signaling inhibitor, when added to background treatment in adults with pulmonary arterial hypertension PAH. This Phase 1b2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial focuses on adults diagnosed with WHO Group 1 PAH who are symptomatic and on stable background therapies. Participants will receive either the experimental HS235 or a placebo, both given by subcutaneous injection. The study evaluates different doses of HS235 alongside at least two approved PAH background treatments and diuretics. The trial has a sequential study model with randomized allocation and quadruple masking to ensure unbiased results. During the study, participants will undergo various assessments including safety monitoring for adverse events up to 29 weeks. Measurements will include pulmonary hemodynamics confirmed by right heart catheterization at screening, exercise capacity via the 6-minute walk test, and adherence to study procedures. The total study duration extends from screening through treatment and follow-up, concluding by November 2028.

CONDITIONS

Brief Title

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here